ABL1 M351T Recombinant Human Active Protein Kinase
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 M351T Recombinant Human Active Protein Kinase is a recombinant ABL1 M351T protein that can be used to study ABL1 M351T-related functions[1].
Product Specifications
UNSPSC
12352211
Target
Bcr-Abl
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
[ABL1M351TRecombinantHumanActiveProteinKinase]
References & Citations
[1]Yusoff YM, et al. Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance. Malays J Pathol. 2024 Dec;46 (3) :431-439.
Shipping Conditions
Room temperature
Scientific Category
Enzyme
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040965-100 1x 100 µL
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470460-100 1x 100 µL
CD44 Standard (156-3C11), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880806-500 1x 500 µL
TYRP1 (Tyrosinase Related Protein 1) (TA99), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940009-500 1x 500 µL
MART-1 / Melan-A (M2-7C10), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details